                         SEQUENCE LISTING

<110>  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE 
       SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
       THE CHILDREN'S HOSPITAL OF PHILADELPHIA
 
<120>  ANTIBODY-DRUG CONJUGATES FOR TARGETING CD56-POSITIVE TUMORS

<130>  4239-95196-02

<150>  US 62/199,707
<151>  2015-07-31

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  372
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  1
caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc       60

acctgtgcca tctccgggga cagtgtctct agcaacagtg ctgcttggaa ctggatcagg      120

cagtccccat cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat      180

aatgattatg cagtatctgt gaaaagtcga ataaccatca acccagacac atccaagaac      240

cagttctccc tgcagctgaa ctctgtgact cccgaggaca cggctgtgta ttactgtgca      300

agagagaaca tagcagcttg gacctgggct tttgatatct ggggccaagg gacaatggtc      360

accgtctctt ca                                                          372


<210>  2
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  2

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 
            20                  25                  30          


Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 
        35                  40                  45              


Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 
    50                  55                  60                  


Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 
65                  70                  75                  80  


Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 
                85                  90                  95      


Tyr Tyr Cys Ala Arg Glu Asn Ile Ala Ala Trp Thr Trp Ala Phe Asp 
            100                 105                 110         


Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 
        115                 120                 


<210>  3
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  3
gaaattgtgt tgacgcagtc tccagccacc ctgtctttgt ctccagggga aagagccacc       60

ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct      120

ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc      180

aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cgtgcaggct      240

gaagatgtgg gggtttatta ctgtcagcaa tatcatggta ctccgacgtt cggccaaggg      300

accaaggtgg aaatcaaacg a                                                321


<210>  4
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  4

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Tyr His Gly Thr Pro Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Gly Gln Ala Gly 
            100                 105                 110     


<210>  5
<211>  363
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  5
gaggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc       60

tcctgcaagg cttctggagg caccttcacc ggctactata tgcactgggt gcgacaggcc      120

cctggacaag ggcttgagtg gatgggatgg atcaacccta acagtggtgg cacaaactat      180

gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac      240

atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagatttg      300

agtagtggtt attccggtta ctttgactac tggggccagg gaaccctggt caccgtctcc      360

tca                                                                    363


<210>  6
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  6

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Leu Ser Ser Gly Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  7
<211>  339
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  7
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc       60

atctcctgca ggtctagtca gagcctccta catagtaatg gatacaactt tttggattgg      120

tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc      180

tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagactttac actgaaaatc      240

agcagagtgg aggctgacga tgttggggtt tattactgca tgcaatctct gcaaactccg      300

tggacgttcg gccacgggac caaggtggaa atcaaacga                             339


<210>  8
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  8

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Tyr Asn Phe Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ser 
                85                  90                  95      


Leu Gln Thr Pro Trp Thr Phe Gly His Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg 
    


